Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages

  Hawkins, Shannon M ^a   Loomans, Holli A ^a   Wan, Ying Wooi ^a   Ghosh Choudhury, Triparna ^a   Coffey, Donna ^b   Xiao, Weimin ^c   Liu, Zhandong ^a   Sangi Haghpeykar, Haleh ^a   Anderson, Matthew L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; NUCLEAR RECEPTOR SUBFAMILY 2 GROUP F MEMBER 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEVER IN MITOSIS GENE A RELATED KINASE 2; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETINOIC ACID INDUCED 14 GENE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COUP TRANSCRIPTION FACTOR II; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARY; PILOT PROJECTS; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STROMAL CELLS; SURVIVAL ANALYSIS;

EID: 84879954998     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1081     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Qin J, Wu SP, Creighton CJ, et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature. 2013;493(7431):236- 240.
3. Qin J, Chen X, Xie X, Tsai MJ, Tsai SY. COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis. Proc Natl Acad Sci USA. 2010;107(8):3687-3692.
4. Qin J, Chen X, Yu-Lee LY, Tsai MJ, Tsai SY. Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. Cancer Res. 2010;70(21):8812-8821.
5. Le Dily F, Metivier R, Gueguen MM, et al. COUP-TFI modulates estrogen signaling and influences proliferation, survival and migration of breast cancer cells. Breast Cancer Res Treat. 2008;110(1):69-83. (Pubitemid 351793858)
6. Litchfield LM, Riggs KA, Hockenberry AM, et al. Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells. PloS one. 2012;7(5):e38278.
7. Schafer G, Wissmann C, Hertel J, Lunyak V, Hocker M. Regulation of vascular endothelial growth factor D by orphan receptors hepatocyte nuclear factor-4 α and chicken ovalbumin upstream promoter transcription factors 1 and 2. Cancer Res. 2008;68(2):457-466. (Pubitemid 351380072)
8. Prahalad P, Dakshanamurthy S, Ressom H, Byers SW. Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGFβ receptor kinase in breast cancer cells. PloS one. 2010;5(4):e10023.
9. Shin SW, Kwon HC, Rho MS, Choi HJ, Kwak JY, Park JI. Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Oncol Rep. 2009;21(1):101-106.
10. Navab R, Gonzalez-Santos JM, Johnston MR, et al. Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. Cancer Res. 2004;64(15):5097-5105. (Pubitemid 39006525)
11. Zeitoun K, Takayama K, Michael MD, Bulun SE. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol. 1999;13(2):239-253. (Pubitemid 29067999)
12. Lee DK, Kurihara I, Jeong JW, et al. Suppression of ERα activity by COUP-TFII is essential for successful implantation and decidualization. Mol Endocrinol. 2010;24(5):930-940.
13. Kurihara I, Lee DK, Petit FG, et al. COUP-TFII mediates progesterone regulation of uterine implantation by controlling ER activity. PLoS Genet. 2007;3(6):e102.
14. Petit FG, Jamin SP, Kurihara I, et al. Deletion of the orphan nuclear receptor COUP-TFII in uterus leads to placental deficiency. Proc Natl Acad Sci USA. 2007;104(15):6293-6298. (Pubitemid 47186088)
15. Takamoto N, Kurihara I, Lee K, Demayo FJ, Tsai MJ, Tsai SY. Haploinsufficiency of chicken ovalbumin upstream promoter transcription factor II in female reproduction. Mol Endocrinol. 2005;19(9):2299-2308. (Pubitemid 41252823)
16. Zeitoun K, Takayama K, Michael MD, Bulun SE. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting elements. Mol Endocrinol. 2006;13:239-253.
17. Klinge CM, Silver BF, Driscoll MD, Sathya G, Bambara RA, Hilf R. Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. J Biol Chem. 1997;272(50):31465-31474. (Pubitemid 28013286)
18. Castro J, Torres M, Sovino H, Fuentes A, Boric MA, Johnson MC. P450Arom induction in isolated control endometrial cells by peritoneal fluid from women with endometriosis. Fertil Steril. 2010;94(7):2521-2527.
19. Hawkins SM, Creighton CJ, Han DY, et al. Functional microRNA involved in endometriosis. Mol Endocrinol. 2011;25(5):821-832.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitativePCRand the 2[-δδ C(T)] method. Methods (San Diego, CA 2001;25(4):402-408.
21. Creighton CJ, Fountain MD, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010;70(5):1906-1915.
22. Lee BC, Cha K, Avraham S, Avraham HK. Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol. 2004;24(4):847-851.
23. Suzuki T, Moriya T, Darnel AD, Takeyama J, Sasano H. Immunohistochemical distribution of chicken ovalbumin upstream promoter transcription factor II in human tissues. Mol Cell Endocrinol. 2000;164(1-2):69-75. (Pubitemid 30665501)
24. Sato Y, Suzuki T, Hidaka K, et al. Immunolocalization of nuclear transcription factors,DAX-1andCOUP-TFII, in the normalhuman ovary: correlation with adrenal 4 binding protein/steroidogenic factor-1 immunolocalization during the menstrual cycle. J Clin Endocrinol Metab. 2003;88(7):3415-3420. (Pubitemid 36877523)
25. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
26. Pereira FA, Tsai MJ, Tsai SY. COUP-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci. 2000;57(10):1388-1398.
27. Mancini ML, Terzic A, Conley BA, Oxburgh LH, Nicola T, Vary CP. Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis. Dev Dyn. 2009;238(10):2479-2493.
28. Diez H, Fischer A, Winkler A, et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res. 2007;313(1):1-9. (Pubitemid 44958449)
29. Swift MR, Weinstein BM. Arterial-venous specification during development. Circ Res. 2009;104(5):576-588.
30. LauDH,LewisAD,EhsanMN,Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 1991;51(19):5181-5187.
31. Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim. 2000;36(6):357-361. (Pubitemid 30626747)
32. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3.
33. HuangdaW,Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
34. Hawkins SM, Andreu-Vieyra CV, Jeong J-W, et al. Dysregulation of uterine signaling pathways in progesterone receptor-cre knockout of Dicer. Mol Endocrinol. 2012;26(9):1552-1566.
35. Yu CT, Tang K, Suh JM, Jiang R, Tsai SY, Tsai MJ. COUP-TFII is essential for metanephric mesenchyme formation and kidney precursor cell survival. Development. 2012;139(13):2330-2339.
36. Zeng X, Shaikh FY, Harrison MK, et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene. 2010;29(36):5103-5112.
37. Wang S, Li W, Liu N, et al. Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer. J Cell Biochem. 2012;113(6):1904-1914.
38. Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci. 2010;101(5):1163-1169.
39. Kutty RK, Chen S, Samuel W, et al. Cell density-dependent nuclear/cytoplasmic localization of NORPEG (RAI14) protein. Biochem Biophys Res Commun. 2006;345(4):1333-1341. (Pubitemid 43817879)
40. Samouelian V, Maugard CM, Jolicoeur M, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol. 2004;54(6):497-504. (Pubitemid 40022245) General Medical Sciences